{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:37:45Z","timestamp":1791286665822,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3294,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA093897"],"award-info":[{"award-number":["CA093897"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA55819"],"award-info":[{"award-number":["CA55819"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.exphem.2013.02.008","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T17:26:11Z","timestamp":1361294771000},"page":"547-557.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["NAMPT\/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity"],"prefix":"10.1016","volume":"41","author":[{"given":"Sathisha Upparahalli","family":"Venkateshaiah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmin","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Bam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"van Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Yaccoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2013.02.008_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1042\/BJ20061638","article-title":"The power to reduce: pyridine nucleotides\u2013small molecules with a multitude of functions","volume":"402","author":"Pollak","year":"2007","journal-title":"Biochem J"},{"key":"10.1016\/j.exphem.2013.02.008_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.tem.2008.10.004","article-title":"Nampt: linking NAD biology, metabolism and cancer","volume":"20","author":"Garten","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.exphem.2013.02.008_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/0008-5472.CAN-09-2465","article-title":"The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer","volume":"70","author":"Galli","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2013.02.008_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00018-003-3161-1","article-title":"Enzymology of NAD+ homeostasis in man","volume":"61","author":"Magni","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.exphem.2013.02.008_bib5","doi-asserted-by":"crossref","first-page":"e2267","DOI":"10.1371\/journal.pone.0002267","article-title":"Pharmacological inhibition of nicotinamide phosphoribosyltransferase\/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD","volume":"3","author":"Busso","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2013.02.008_bib6","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis","volume":"63","author":"Hasmann","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2013.02.008_bib7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nm.1906","article-title":"Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner","volume":"15","author":"Van","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.exphem.2013.02.008_bib8","doi-asserted-by":"crossref","first-page":"e7897","DOI":"10.1371\/journal.pone.0007897","article-title":"Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE","volume":"4","author":"Bruzzone","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2013.02.008_bib9","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2008-08-173369","article-title":"The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies","volume":"113","author":"Nahimana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib10","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1182\/blood-2012-03-416776","article-title":"Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1\/2) inhibition","volume":"120","author":"Cea","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib11","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood-2011-05-350322","article-title":"Could CR mean cure?","volume":"118","author":"Barlogie","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib13","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3324\/haematol.2012.066555","article-title":"Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data","volume":"98","author":"Waheed","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2013.02.008_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2010.08141.x","article-title":"Advances in the understanding of myeloma bone disease and tumour growth","volume":"149","author":"Yaccoby","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2013.02.008_bib15","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/0008-5472.CAN-03-1131","article-title":"Cancer and the microenvironment: myeloma-osteoclast interactions as a model","volume":"64","author":"Yaccoby","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2013.02.008_bib16","doi-asserted-by":"crossref","first-page":"7599","DOI":"10.1158\/1078-0432.CCR-05-0523","article-title":"The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype","volume":"11","author":"Yaccoby","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2013.02.008_bib17","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-2141.2007.06742.x","article-title":"Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines","volume":"138","author":"Li","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2013.02.008_bib18","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib19","first-page":"192","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model","volume":"91","author":"Yaccoby","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2013.02.008_bib20","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID-rab model: a novel in\u00a0vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells","volume":"18","author":"Yata","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.02.008_bib21","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","article-title":"Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations","volume":"92","author":"Yaccoby","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib22","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/blood.V94.10.3576.422k01_3576_3582","article-title":"The proliferative potential of myeloma plasma cells manifest in the SCID-hu host","volume":"94","author":"Yaccoby","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib23","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in\u00a0vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib24","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"de MG. Poly(ADP-ribose): novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.exphem.2013.02.008_bib26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrd1718","article-title":"Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors","volume":"4","author":"Jagtap","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2013.02.008_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cmet.2007.11.006","article-title":"Conserved metabolic regulatory functions of sirtuins","volume":"7","author":"Schwer","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.exphem.2013.02.008_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in\u00a0vivo","volume":"84","author":"Pennisi","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2013.02.008_bib29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5483\/BMBRep.2008.41.11.751","article-title":"SIRT1: roles in aging and cancer","volume":"41","author":"Kim","year":"2008","journal-title":"BMB Rep"},{"key":"10.1016\/j.exphem.2013.02.008_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12013-008-9041-4","article-title":"The NAD World: A new systemic regulatory network for metabolism and aging\u2013Sirt1, systemic NAD biosynthesis, and their importance","volume":"53","author":"Imai","year":"2009","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.exphem.2013.02.008_bib31","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \"BRCAness\" sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib32","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1124\/jpet.111.184630","article-title":"Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells","volume":"338","author":"Travelli","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.exphem.2013.02.008_bib33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2010-04-279539","article-title":"Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma","volume":"117","author":"Walker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib34","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID-rab model: A novel in\u00a0vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells","volume":"18","author":"Yata","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2013.02.008_bib35","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","article-title":"Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations","volume":"92","author":"Yaccoby","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib36","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/blood.V94.10.3576.422k01_3576_3582","article-title":"The proliferative potential of myeloma plasma cells manifest in the SCID-hu host","volume":"94","author":"Yaccoby","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2013.02.008_bib37","first-page":"192","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model","volume":"91","author":"Yaccoby","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2013.02.008_bib38","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in\u00a0vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X13000568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X13000568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:30:38Z","timestamp":1759566638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X13000568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0301472X13000568"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2013.02.008","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NAMPT\/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2013.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}